ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
Want to see AVBP full AI Analyst Report?
Top Page
ArriVent BioPharma, Inc.
(NASDAQ:AVBP)
Select Model
Select Model
Rating:59Neutral
Price Target:
$34.00
▲(14.71% Upside)
Action:Reiterated
Date:06/23/26
The score reflects a well-capitalized, very low-debt balance sheet and strong recent technical momentum, partially offset by the dominant fundamental risks of being pre-revenue with sizable losses and continued cash burn. Valuation is not supportive given negative earnings, while the corporate event is mildly positive but secondary.
Positive Factors
Low Leverage / Strong Balance Sheet
Extremely low debt and a materially larger asset base reduce short-term refinancing risk and provide operational runway for clinical programs. This durable capital structure gives strategic optionality to fund trials, pursue partnerships, or withstand trial timelines before revenue realization.
Negative Factors
Pre-Revenue with Widening Losses
Sizable and increasing net losses reflect ongoing investment in trials without product revenue. Over multiple years this erodes returns and necessitates continued funding; long-term viability depends on clinical success or new funding sources rather than operational cash flow.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
Extremely low debt and a materially larger asset base reduce short-term refinancing risk and provide operational runway for clinical programs. This durable capital structure gives strategic optionality to fund trials, pursue partnerships, or withstand trial timelines before revenue realization.
Read all positive factors
ArriVent BioPharma, Inc. (AVBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.52B
Dividend YieldN/A
Average Volume (3M)517.16K
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue GrowthN/A
EPS Growth6.28%
CountryUS
Employees52
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.53
Shares Outstanding46,574,930
10 Day Avg. Volume485,884
30 Day Avg. Volume517,157
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.63
Forecast
1Y Price Target
$43.08Price Target Upside45.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-4
Revenue Forecast (FY)N/A
ArriVent BioPharma, Inc. Business Overview & Revenue Model
Company Description
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, advancing, and bringing to market treatments addressing critical gaps in cancer patient care. The company specifically focuses on developing and commerci...
How the Company Makes Money
null...
ArriVent BioPharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -145.24M | -166.31M | -80.49M | -69.33M | 0.00 | -51.61M |
| Net Income | -145.24M | -166.31M | -80.49M | -69.33M | -36.91M | -51.61M |
Balance Sheet | ||||||
| Total Assets | 349.30M | 333.17M | 274.94M | 163.10M | 182.83M | 43.04M |
| Cash, Cash Equivalents and Short-Term Investments | 326.38M | 312.82M | 218.86M | 150.39M | 163.37M | 37.28M |
| Total Debt | 419.00K | 14.00K | 176.00K | 317.00K | 139.00K | 0.00 |
| Total Liabilities | 25.32M | 25.95M | 17.29M | 11.80M | 8.37M | 1.82M |
| Stockholders Equity | 323.98M | 307.22M | 257.65M | 151.30M | 174.46M | 41.22M |
Cash Flow | ||||||
| Free Cash Flow | -134.47M | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
| Operating Cash Flow | -134.47M | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
| Investing Cash Flow | -104.47M | -71.23M | -192.47M | 0.00 | 0.00 | -40.00M |
| Financing Cash Flow | 251.18M | 203.06M | 186.58M | 42.86M | 169.72M | 89.87M |
ArriVent BioPharma, Inc. Technical Analysis
Positive
29.64
Price Trends
29.51
Positive
26.38
Positive
23.46
Positive
Market Momentum
0.83
Negative
64.72
Neutral
67.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVBP, the sentiment is Positive. The current price of 29.64 is below the 20-day moving average (MA) of 30.10, above the 50-day MA of 29.51, and above the 200-day MA of 23.46, indicating a bullish trend. The MACD of 0.83 indicates Negative momentum. The RSI at 64.72 is Neutral, neither overbought nor oversold. The STOCH value of 67.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVBP.
ArriVent BioPharma, Inc. Risk Analysis
ArriVent BioPharma, Inc. disclosed 92 risk factors in its most recent earnings report. ArriVent BioPharma, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ArriVent BioPharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.84B | ― | -56.07% | ― | 3.42% | -11.04% | |
59 Neutral | $1.52B | -9.26 | -48.98% | ― | ― | 6.28% | |
59 Neutral | $1.81B | -4.41 | -50.17% | ― | 34.26% | 23.00% | |
55 Neutral | $2.78B | -12.65 | -145.81% | ― | -10.44% | 19.99% | |
52 Neutral | $3.46B | ― | -43.94% | ― | 39.04% | 29.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $811.25M | -1.58 | 1870.38% | ― | -50.80% | 14.80% |
* Healthcare Sector Average
AVBP
ArriVent BioPharma, Inc.
32.70
9.90
43.42%
QURE
uniQure
44.39
30.44
218.21%
IOVA
Iovance Biotherapeutics
4.06
2.21
119.46%
RLAY
Relay Therapeutics
17.28
14.05
434.98%
IVA
Inventiva
3.51
0.11
3.24%
TSHA
Taysha Gene Therapies
6.53
4.04
162.25%
ArriVent BioPharma, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
ArriVent BioPharma Stockholders Back Board and Auditor Slate
Positive
Jun 22, 2026
On June 18, 2026, ArriVent BioPharma, Inc. held its 2026 annual meeting of stockholders via live audio webcast, with a quorum of 72.07% of eligible shares represented. Stockholders elected James Healy, M.D., Ph.D., John Hohneker, M.D., and Stuart ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
ArriVent BioPharma Updates At-The-Market Equity Offering Program
Neutral
May 11, 2026
On May 11, 2026, ArriVent BioPharma, Inc. filed a prospectus supplement with the U.S. Securities and Exchange Commission to update its existing at-the-market equity offering program. Under this supplement, the company may, from time to time, sell ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.